Interaction with other drugs
The main isoenzyme involved in the metabolism of simeprevira is . Thus, the possible development of mediated isoenzyme anadrol resultsclinically relevant effects of other drugs on the pharmacokinetics of simeprevira.
Simeprevir does not have an inducing effect on isozymes in human hepatocytes. According to studies in vitro simeprevir is a moderate inhibitor of isozymes and a weak inhibitor of isozyme and . Simeprevir is not clinically significant enzyme activity inhibitor of cathepsin.
According to studies in vitro simeprevir is a substrate of transport proteins, drugs, including P-glycoprotein. Simeprevir inhibits the transport proteins capture and, and also transport proteins active excretion from the cell P-glycoprotein proteins involved in the transport of bilirubin in the hepatocytes and back.
Joint application with powerful simeprevira or moderate anadrol resultsisoenzyme inhibitors can lead to a significant increase in the plasma concentration simeprevira, while combined application with strong or moderate isoenzyme inducers can significantly reduce simeprevira concentration in plasma and lead to a loss of efficiency. Thus, it is not recommended the combined use drug Sovriad with substances that are potent or moderate inhibitors or inducers isoenzyme activity.
Simeprevir is a weak inhibitor of isoenzyme in the gut, whereas the effect on the activity of in liver absent. The combined use of the drug Sovriad with drugs metabolized mainly isoenzyme may lead to increased concentrations of these drugs in plasma.
Joint application with medicament preparations, which are transport proteins OATP1B1 substrates and P-glycoprotein may increase the concentration of drugs in plasma.
The information on the interaction of peginterferon alfa and ribavirin with other drugs given in the corresponding instructions for use.
Not allowed the use of the drug as monotherapy. Simeprevir should be administered in combination with peginterferon alfa and ribavirin. Thus, prior to initiation of therapy should be familiar with the instructions on the use of peginterferon alfa and ribavirin.
Special instructions described for peginterferon alfa and ribavirin, the same will apply to combination therapy with simeprevirom.
Pregnancy and contraception requirements
Since Sovriad medicament for use in combination with peginterferon alfa and ribavirin combination therapy to apply instructions relating to pregnancy and contraception requirements for all drugs that are part of the combination.
Ribavirin can cause birth defects anadrol resultsdeath of the fetus in utero. Therefore, you must exercise extreme caution in order to avoid pregnancy in treated women and in female partners of men undergoing treatment. See. Also on the use of ribavirin instructions.
Fertility, women and their partners, as well as being treated men with their female partners during therapy and during the period specified in the instructions for use of ribavirin, after its terminations it should use a combination of two effective methods of contraception.